PRODUCT NAME

Bevacizumab Biosimilar - Research Grade

SPECIES REACTIVITY

Human

HOST

Humanized

SPECIFICITY

Detects human VEGF. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. This product is for research use only.

PURIFICATION METHOD

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

ANTIGEN DISTRIBUTION

IMMUNOGEN

CONCENTRATION

FORMULATION

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

PURITY

>95% by SDS-PAGE and HPLC

ENDOTOXIN

≤ 0.75 EU/mg as determined by the LAL method

AGGRIGATION

STORAGE CONDITION

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

TARGET

VEGF

CLONE

SYNONYMS

BACKGROUND

Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium.

UNIPROT

PATHOGEN TEST

APPLICATIONS

APPLICATION NOTES

USAGE

Products are for research use only. Not for use in diagnostic or therapeutic procedures.